TY  - JOUR
A1  - Bassan, Renato
A1  - Hoelzer, Dieter
A1  - Thomas, Xavier
A1  - Montesinos, Pau
A1  - Pavlu, Jiri
A1  - McKendrick, Jan
A1  - Kudlac, Amber
A1  - Barlev, Arie
A1  - Barber, Beth
A1  - Cong, Ze
T1  - Clinician concepts of cure in adult relapsed and refractory philadelphia-negative b cell precursor acute lymphoblastic leukemia: A delphi study
T2  - Advances in therapy
N2  - Introduction: Despite the poor prognosis for adults with relapsed or refractory (RR) Philadelphia chromosome (Ph)-negative B cell precursor acute lymphoblastic leukemia (ALL), long-term survival is possible and may even be considered as "cure".
Methods: This study used a Delphi panel approach to explore concepts of cure in RR Ph-negative B cell precursor ALL. Ten European experts in this disease area participated in a survey and face-to-face panel meeting.
Results: Findings showed that clinicians conceptualize "cure" as a combination of three broad treatment outcomes that vary depending on the treatment stage: complete remission early in treatment (1–3 months) indicates initial success; eradicating cancer cells (minimal residual disease negative status) consolidates the early clinical response; leukemia-free survival is required in the long term.
Conclusions: Although such terminology remains contested, clinicians would begin considering "cure" as early as 2 years provided the patient is off therapy, with most considering the term applicable by the third year.
Funding: Amgen Inc.
KW  - B cell precursor acute lymphoblastic leukemia
KW  - Cure
KW  - Oncology
KW  - Outcomes
KW  - Refractory ALL
KW  - Relapsed ALL
KW  - Survival
Y1  - 2019
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/53438
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-534387
SN  - 1865-8652
N1  - Open Access: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
VL  - 36
IS  - 4
SP  - 870
EP  - 879
PB  - Springer Healthcare Communications
CY  - Tarporley
ER  -